Which medication requires a 2-week overlap with oral medication for administration?

The requirement for a 2-week overlap with an oral medication is specifically relevant for Abilify Maintena, which is a long-acting injectable formulation of aripiprazole. This overlap is necessary to ensure that the patient maintains a therapeutic level of the medication in their system while transitioning from oral to injectable administration.

Abilify Maintena is typically initiated in patients who have been stabilized on oral aripiprazole, and the 2-week overlap allows for the gradual buildup of the long-acting formulation while the patient still benefits from the immediate effect of the oral formulation. This strategy helps to minimize the risk of relapse during the initiation of treatment with the long-acting injectable.

In contrast, the other medications listed do not have this specific requirement for an overlap period in the same context. Each of those drugs serves different therapeutic purposes and dosing schedules, making them distinct from the transition protocols required for Abilify Maintena. This is vital to consider when managing patient care and ensuring medication efficacy.